CHOLYBAR Drug Patent Profile
✉ Email this page to a colleague
When do Cholybar patents expire, and when can generic versions of Cholybar launch?
Cholybar is a drug marketed by Parke Davis and is included in two NDAs.
The generic ingredient in CHOLYBAR is cholestyramine. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cholybar
A generic version of CHOLYBAR was approved as cholestyramine by EPIC PHARMA LLC on August 15th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CHOLYBAR?
- What are the global sales for CHOLYBAR?
- What is Average Wholesale Price for CHOLYBAR?
Summary for CHOLYBAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Clinical Trials: | 2 |
| DailyMed Link: | CHOLYBAR at DailyMed |
Recent Clinical Trials for CHOLYBAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1 |
| City of Hope Medical Center | Phase 1 |
| City of Hope Medical Center | Phase 2 |
US Patents and Regulatory Information for CHOLYBAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | CHOLYBAR | cholestyramine | BAR, CHEWABLE;ORAL | 071621-001 | May 26, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Parke Davis | CHOLYBAR | cholestyramine | BAR, CHEWABLE;ORAL | 071739-001 | May 26, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CHOLYBAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Parke Davis | CHOLYBAR | cholestyramine | BAR, CHEWABLE;ORAL | 071621-001 | May 26, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| Parke Davis | CHOLYBAR | cholestyramine | BAR, CHEWABLE;ORAL | 071739-001 | May 26, 1988 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CHOLYBAR
See the table below for patents covering CHOLYBAR around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
